Clostridioides difficile epidemiology in the Middle and the Far East

Anaerobe. 2022 Apr:74:102542. doi: 10.1016/j.anaerobe.2022.102542. Epub 2022 Feb 28.

Abstract

Objectives: Clostridioides difficile is an important pathogen of healthcare-associated gastrointestinal infections. Recently, an increased number of C. difficile infection (CDI) surveillance data has been reported from Asia. The aim of this review is to summarize the data on the prevalence, distribution and molecular epidemiology of CDI in the Middle and the Far East.

Methods: Literature was drawn from a search of PubMed up to September 30, 2021.

Results: The meta-analysis of data from 111 studies revealed the pooled CDI prevalence rate in the Middle and the Far East of 12.4% (95% CI 11.4-13.3); 48 studies used PCR for CDI laboratory diagnoses. The predominant types (RT)/sequence type (ST) differ between individual countries (24 studies, 14 countries). Frequently found RTs were 001, 002, 012, 017, 018 and 126; RT017 was predominant in the Far East. The epidemic RT027 was detected in 8 countries (22 studies), but its predominance was reported only in three studies (Israel and Iran). The contamination of vegetable and meat or meat products and/or intestinal carriage of C. difficile in food and companion animals have been reported; the C. difficile RTs/STs identified overlapped with those identified in humans.

Conclusions: A large number of studies on CDI prevalence in humans from the Middle and the Far East have been published; countries with no available data were identified. The number of studies on C. difficile from non-human sources is limited. Comparative genomic studies of isolates from different sources are needed.

Keywords: Antimicrobial susceptibility testing; Clostridioides difficile; Epidemiology; Middle and Far East; Typing.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Asia, Eastern
  • Clostridioides
  • Clostridioides difficile* / genetics
  • Clostridium Infections* / drug therapy
  • Clostridium Infections* / epidemiology
  • Cross Infection* / epidemiology
  • Humans
  • Ribotyping

Substances

  • Anti-Bacterial Agents